Denosumab reduces secondary fragility fracture risk in osteoporotic women
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosisClimacteric. 2015 Jun 1:1-23
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
7808 osteoperotic women part of the FREEDOM study, were analyzed in this post-hoc analysis. The purpose of this study was to determine how efficacious denosumab (60mg for 36 months) was in preventing fragility fractures and secondary fragility fractures as compared to a placebo. Results indicated that prior fragility fracture was present in 45% of the population, and denosumab treatment significan...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE